Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in J Thorac Oncol Retrieve available abstracts of 356 articles: HTML format

Single Articles

September 2025
1. KIM H, Jo E, Kim J, Jang SH, et al
   Screening-Detected versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality.
   J Thorac Oncol. 2025 Sep 4:S1556-0864(25)01038.
   PubMed     Abstract available
   
   
   
2. CHEN CC, Chen SC
   Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
   J Thorac Oncol. 2025;20:e99-e100.
   PubMed    
   
   
   
3. RODE MM, Midthun DE
   A Response to the Letter to the Editor: Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
   J Thorac Oncol. 2025;20:e100-e101.
   PubMed    
   
   
   
4. LEONG TL, Steinfort DP
   Broadening the Scope of Bronchoscopic Sampling in the Era of Minimally Invasive and Molecular Diagnosis of Lung Cancer.
   J Thorac Oncol. 2025;20:1172-1176.
   PubMed    
   
   
   
5. DE GROOT P, Erasmus J, Vlahos I
   Lung Cancer Screening: Future Opportunities.
   J Thorac Oncol. 2025;20:1152-1155.
   PubMed    
   
   
   
6. PARK S, Ahn HK, Lee S, Min YJ, et al
   Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
   J Thorac Oncol. 2025;20:1279-1288.
   PubMed     Abstract available
   
   
   August 2025
7. KENMOTSU H, Saito Y, Ninomiya K, Uematsu S, et al
   Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME).
   J Thorac Oncol. 2025 Aug 18:S1556-0864(25)01014.
   PubMed     Abstract available
   
   
   
8. ENG L, Evans WK, Eisele M, Nishimura KK, et al
   The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
   J Thorac Oncol. 2025 Aug 4:S1556-0864(25)00824.
   PubMed     Abstract available
   
   
   
9. HERBST RS, Prizant H, Ruderman D, Conway J, et al
   Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials.
   J Thorac Oncol. 2025 Aug 2:S1556-0864(25)00983.
   PubMed     Abstract available
   
   
   
10. BANERJEE A, Vathiotis I, Halder D, Sen U, et al
    Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity.
    J Thorac Oncol. 2025 Aug 2:S1556-0864(25)00773.
    PubMed     Abstract available
    
    
    
11. AL-RABI K, El Khatib O, Abdeljalil R, Talab Y, et al
    Lung Cancer in Jordan.
    J Thorac Oncol. 2025;20:1007-1017.
    PubMed    
    
    
    
12. NAKAZAWA S, Pecci F, Ricciuti B, Gottlieb FH, et al
    Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
    J Thorac Oncol. 2025;20:1035-1049.
    PubMed     Abstract available
    
    
    
13. ZHANG B, Shah KB, Parma M, Wang K, et al
    Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report.
    J Thorac Oncol. 2025;20:1131-1138.
    PubMed     Abstract available
    
    
    July 2025
14. JANNE PA, Goto Y, Kubo T, Ninomiya K, et al
    Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer.
    J Thorac Oncol. 2025 Jul 30:S1556-0864(25)00981.
    PubMed     Abstract available
    
    
    
15. CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
    The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database.
    J Thorac Oncol. 2025 Jul 28:S1556-0864(25)00813.
    PubMed     Abstract available
    
    
    
16. SMELTZER MP, King JC, Connolly C, Brunson K, et al
    The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing.
    J Thorac Oncol. 2025 Jul 22:S1556-0864(25)00937.
    PubMed     Abstract available
    
    
    
17. ALDEA M, Rotow JK, Arcila M, Hatton M, et al
    Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2025 Jul 7:S1556-0864(25)00831.
    PubMed     Abstract available
    
    
    
18. NAIDOO J, Niroula A, Uprety D, Smeltzer M, et al
    50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic.
    J Thorac Oncol. 2025 Jul 3:S1556-0864(25)00819.
    PubMed    
    
    
    
19. JIN D, Wu J, Xing W
    Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations.
    J Thorac Oncol. 2025;20:e89-e90.
    PubMed    
    
    
    
20. TAYLOR KL, Williams RM, Meza R, Smith P, et al
    Reducing Lung Cancer Mortality by Providing Smoking Cessation Support in the Lung Cancer Screening Setting: Missed Opportunities and Lessons Learned on Both Sides of the Atlantic.
    J Thorac Oncol. 2025;20:847-855.
    PubMed     Abstract available
    
    
    
21. BRUSTUGUN OT, Gronberg BH, Aanerud M, Paulsen EE, et al
    Lung Cancer in Norway.
    J Thorac Oncol. 2025;20:839-846.
    PubMed    
    
    
    
22. KILICKAP S, Baramidze A, Sezer A, Ozguroglu M, et al
    Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
    J Thorac Oncol. 2025;20:941-954.
    PubMed     Abstract available
    
    
    
23. WU YL, Kim HR, Soo RA, Zhou Q, et al
    First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.
    J Thorac Oncol. 2025;20:955-968.
    PubMed     Abstract available
    
    
    June 2025
24. FUKUDA K, Nanjo S, Takeuchi S, Chakrabarti T, et al
    Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer.
    J Thorac Oncol. 2025 Jun 13:S1556-0864(25)00766.
    PubMed     Abstract available
    
    
    
25. PETERS S, Regan MM, Paz-Ares LG, Reck M, et al
    Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749.
    PubMed     Abstract available
    
    
    
26. MASCAUX C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, et al
    Advances in lung cancer basic and translational research in 2025 - Overview and perspectives focusing on non-small cell lung cancer.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754.
    PubMed     Abstract available
    
    
    
27. TAMMEMAGI MC, Borondy-Kitts A, Field JF, Mohan A, et al
    A Response to the Letter to the Editor: "Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?".
    J Thorac Oncol. 2025;20:e69-e71.
    PubMed    
    
    
    
28. MEERBEECK JV, Hal GV, Snoeckx A
    Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?
    J Thorac Oncol. 2025;20:e68-e69.
    PubMed    
    
    
    
29. REVEL MP
    Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule Strategy.
    J Thorac Oncol. 2025;20:705-707.
    PubMed    
    
    
    
30. FU F, Chen H
    Bridging the Gap in Surgery for Octogenarians With Early-Stage Lung Cancer.
    J Thorac Oncol. 2025;20:703-704.
    PubMed    
    
    
    
31. SCHEFFLER M, Wolf J, Michels S
    Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
    J Thorac Oncol. 2025;20:692-694.
    PubMed    
    
    
    
32. SPIRA AI, Paz-Ares L, Han JY, Shih JY, et al
    Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
    J Thorac Oncol. 2025;20:809-816.
    PubMed     Abstract available
    
    
    
33. MAO S, Liu X, Wang L, Wang Y, et al
    AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.
    J Thorac Oncol. 2025;20:739-749.
    PubMed     Abstract available
    
    
    May 2025
34. CHADDHA U, Agrawal A, Ghori U, Kheir F, et al
    Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology (AABIP) and International Association for the Study of Lung Cancer (IASLC) Clinical Practic
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00722.
    PubMed     Abstract available
    
    
    
35. HERBST RS, Cho BC, Zhou C, Burotto M, et al
    Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study.
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00724.
    PubMed     Abstract available
    
    
    
36. KREBS MG, Cho BC, Hiret S, Han JY, et al
    Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
    J Thorac Oncol. 2025 May 16:S1556-0864(25)00720.
    PubMed     Abstract available
    
    
    
37. RODE MM, Sykes AG, Allen MS, Ingalls LA, et al
    Risk-Based Lung Cancer Screening in Clinical Practice.
    J Thorac Oncol. 2025 May 14:S1556-0864(25)00717.
    PubMed     Abstract available
    
    
    
38. JONES SB, Chan C, Filippi AR, Harada K, et al
    Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommi
    J Thorac Oncol. 2025 May 9:S1556-0864(25)00710.
    PubMed     Abstract available
    
    
    
39. WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al
    Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
    J Thorac Oncol. 2025 May 7:S1556-0864(25)00706.
    PubMed     Abstract available
    
    
    
40. SABARI JK, Yu HA, Mahadevia PJ, Liu Y, et al
    Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
    J Thorac Oncol. 2025 May 2:S1556-0864(25)00699.
    PubMed     Abstract available
    
    
    
41. BOSTOCK I, Fox A, Engelhart K, Farjah F, et al
    Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly With Lung Cancer Patients: Recognized Risks, Unmet Needs".
    J Thorac Oncol. 2025;20:e63-e64.
    PubMed    
    
    
    
42. WANG F, Bao M, Zhu L
    Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs.
    J Thorac Oncol. 2025;20:e62-e63.
    PubMed    
    
    
    
43. MREMI A, Ndumbalo J, Chuwa H, Henke O, et al
    Lung Cancer in Tanzania.
    J Thorac Oncol. 2025;20:560-564.
    PubMed    
    
    
    
44. DE-TORRES JP, Varo N
    The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs.
    J Thorac Oncol. 2025;20:555-556.
    PubMed    
    
    
    
45. YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al
    Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
    J Thorac Oncol. 2025;20:676-679.
    PubMed     Abstract available
    
    
    
46. LINDBERG A, Muhl L, Yu H, Hellberg L, et al
    In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.
    J Thorac Oncol. 2025;20:625-640.
    PubMed     Abstract available
    
    
    April 2025
47. GRONBERG BH, Killingberg KT, Flotten O, Bjaanaes MM, et al
    High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00696.
    PubMed     Abstract available
    
    
    
48. GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
    Surveillance with [(18)F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00693.
    PubMed     Abstract available
    
    
    
49. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L).
    J Thorac Oncol. 2025 Apr 9:S1556-0864(25)00656.
    PubMed     Abstract available
    
    
    
50. BOERI M, Zanghi A, Pastorino U
    New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges.
    J Thorac Oncol. 2025;20:422-424.
    PubMed    
    
    
    
51. KIM YW, Lee CT
    Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
    J Thorac Oncol. 2025;20:419-421.
    PubMed    
    
    
    
52. PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al
    Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
    J Thorac Oncol. 2025;20:411-414.
    PubMed    
    
    
    
53. XIA Y, Wang K, Zhao J, Arter Z, et al
    Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
    J Thorac Oncol. 2025;20:465-474.
    PubMed     Abstract available
    
    
    
54. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
    J Thorac Oncol. 2025;20:487-499.
    PubMed     Abstract available
    
    
    
55. BLECHTER B, Hsiung CA, Wang X, Zhang H, et al
    Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
    J Thorac Oncol. 2025;20:521-530.
    PubMed     Abstract available
    
    
    
56. LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al
    Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
    J Thorac Oncol. 2025;20:451-464.
    PubMed     Abstract available
    
    
    March 2025
57. SEDER CW, Chang SC, Towe CW, Puri V, et al
    Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge Resection for Stage IA (
    J Thorac Oncol. 2025 Mar 23:S1556-0864(25)00641.
    PubMed     Abstract available
    
    
    
58. HAKOZAKI T, Tanaka K, Shiraishi Y, Sekino Y, et al
    Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON).
    J Thorac Oncol. 2025 Mar 7:S1556-0864(25)00106.
    PubMed     Abstract available
    
    
    
59. CHEN P, Wang H, Tang Z, Shi J, et al
    Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells.
    J Thorac Oncol. 2025 Mar 6:S1556-0864(25)00109.
    PubMed     Abstract available
    
    
    
60. BROWN M, Myers R, Lam S
    Enlarging the Reach of Screening and Early Detection of Lung Cancer.
    J Thorac Oncol. 2025;20:249-251.
    PubMed    
    
    
    
61. CHOU TY, Dacic S, Wistuba I, Beasley MB, et al
    Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2025;20:311-330.
    PubMed     Abstract available
    
    
    
62. LU S, Wu L, Wang Q, Wang Z, et al
    Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    J Thorac Oncol. 2025;20:366-382.
    PubMed     Abstract available
    
    
    
63. MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al
    Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Thorac Oncol. 2025;20:285-295.
    PubMed     Abstract available
    
    
    February 2025
64. XIE D, Zhang L, He N, Yang C, et al
    Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography in Average-Risk Populations in China.
    J Thorac Oncol. 2025 Feb 13:S1556-0864(25)00072.
    PubMed     Abstract available
    
    
    
65. CALLES A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al
    Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study.
    J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064.
    PubMed     Abstract available
    
    
    
66. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    Corrigendum to 'The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer' [Journal of Thoraci
    J Thorac Oncol. 2025 Feb 9:S1556-0864(25)00050.
    PubMed    
    
    
    
67. HAN B, Liu J, Wu L, Zhao Y, et al
    Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00062.
    PubMed     Abstract available
    
    
    
68. LI YS, Yu Q, Bu Q, Lin L, et al
    First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00063.
    PubMed     Abstract available
    
    
    
69. ABBAR B, Labreche K, Cadranel J, Veyri M, et al
    HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Feb 7:S1556-0864(25)00060.
    PubMed     Abstract available
    
    
    
70. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Failure to Include Nonsmokers in Computed Tomography Screening for Lung Cancer is Unjust".
    J Thorac Oncol. 2025;20:e39-e40.
    PubMed    
    
    
    
71. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges".
    J Thorac Oncol. 2025;20:e36-e37.
    PubMed    
    
    
    
72. LI J, Zhang Y, Fu T, Tong Y, et al
    Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges.
    J Thorac Oncol. 2025;20:e35-e36.
    PubMed    
    
    
    
73. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening".
    J Thorac Oncol. 2025;20:e34.
    PubMed    
    
    
    
74. CUI Y
    Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e33-e34.
    PubMed    
    
    
    
75. RIZZO MM, Barros M, Chimondeguy D, Dalurzo ML, et al
    Lung Cancer in Argentina.
    J Thorac Oncol. 2025;20:144-149.
    PubMed    
    
    
    
76. BAK M, Park H, Lee SH, Lee N, et al
    The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.
    J Thorac Oncol. 2025;20:167-176.
    PubMed     Abstract available
    
    
    
77. NAKAGAWA K, Watanabe SI, Wakabayashi M, Yotsukura M, et al
    Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
    J Thorac Oncol. 2025;20:157-166.
    PubMed     Abstract available
    
    
    
78. LEE J, Jeon JH, Chung JH, Son JW, et al
    Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I Invasive Nonmucinous Adenocarcinoma.
    J Thorac Oncol. 2025;20:194-202.
    PubMed     Abstract available
    
    
    January 2025
79. LIAO W, Ray MA, Patel A, Roma J, et al
    Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
    J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057.
    PubMed     Abstract available
    
    
    
80. BOSTOCK IC, Fox AH, Ward RC, Engelhardt KE, et al
    Outcomes After Surgical Management of Early-Stage Lung Cancer in Octogenarians: An in-depth Analysis of a Nationally Representative Cohort.
    J Thorac Oncol. 2025 Jan 28:S1556-0864(25)00053.
    PubMed     Abstract available
    
    
    
81. TAMMEMAGI MC, Borondy-Kitts A, Field JK, Henschke CI, et al
    Lung cancer screening program quality indicators - review & recommendations - An International Association for the Study of Lung Cancer Delphi process study.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00052.
    PubMed     Abstract available
    
    
    
82. GANDHI MM, Elkrief A, Moore CG, Ricciuti B, et al
    Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00049.
    PubMed     Abstract available
    
    
    
83. TSAO MS, Rosenthal A, Nicholson AG, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00046.
    PubMed     Abstract available
    
    
    
84. AKAMATSU H, Sakata S, Azuma K, Yoshioka H, et al
    A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
    J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007.
    PubMed     Abstract available
    
    
    
85. GENDARME S, Irajizad E, Long JP, Fahrmann JF, et al
    Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials.
    J Thorac Oncol. 2025 Jan 9:S1556-0864(25)00004.
    PubMed     Abstract available
    
    
    
86. BESSE B, Goto K, Wang Y, Lee SH, et al
    Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550.
    PubMed     Abstract available
    
    
    
87. FUKUI T, Mamesaya N, Takahashi T, Kishi K, et al
    A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548.
    PubMed     Abstract available
    
    
    
88. DOWLATI A, Chiang AC, Cervantes A, Babu S, et al
    Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549.
    PubMed     Abstract available
    
    
    
89. HUBER RM, Lam S, Cavic M, Balata H, et al
    Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C Leiman Regarding the Manuscript "Terminology Issues in Screening and Early Detection of Lung Cancer-International Association for the Study of Lung Cancer Early Detectio
    J Thorac Oncol. 2025;20:e6-e8.
    PubMed    
    
    
    
90. PENG J, Zhao L, Shan D
    Enhancing Clinical Precision and Patient Communication in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e3-e4.
    PubMed    
    
    
    
91. GADGEEL SM, Jensen E, Shamoun M, Rajagopalan K, et al
    Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025;20:e11-e12.
    PubMed    
    
    
    
92. BORGHAEI H, Mok T
    Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
    J Thorac Oncol. 2025;20:17-19.
    PubMed    
    
    
    
93. LI HJ, Qiu ZB, Wang MM, Zhang C, et al
    Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma.
    J Thorac Oncol. 2025;20:52-64.
    PubMed     Abstract available
    
    
    
94. PETERS S, Cho BC, Luft AV, Alatorre-Alexander J, et al
    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
    J Thorac Oncol. 2025;20:76-93.
    PubMed     Abstract available
    
    
    December 2024
95. WARKENTIN MT, Tammemagi MC, Vakil E, Bedard ELR, et al
    Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening.
    J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546.
    PubMed     Abstract available
    
    
    
96. LEE JB, Choi SJ, Shim HS, Park BJ, et al
    Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).
    J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544.
    PubMed     Abstract available
    
    
    
97. GABE R, Crosbie PAJ, Vulkan D, Bailey H, et al
    Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.
    J Thorac Oncol. 2024 Dec 19:S1556-0864(24)02535.
    PubMed     Abstract available
    
    
    
98. PASSIGLIA F, Listi A, Bironzo P, Merlini A, et al
    Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA).
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529.
    PubMed     Abstract available
    
    
    
99. SWALDUZ A, Schiffler C, Curcio H, Ambasager B, et al
    LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530.
    PubMed     Abstract available
    
    
    
100. TAVERNARI D, Borgeaud M, Liu X, Kaushal P, et al
     Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02531.
     PubMed     Abstract available
     
     
     
101. HOFFMANN H, Nicholson AG, Detterbeck FC, Tsao MS, et al
     The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surge
     J Thorac Oncol. 2024 Dec 13:S1556-0864(24)02526.
     PubMed     Abstract available
     
     
     
102. KIM SY, Silvestri GA, Kim YW, Kim RY, et al
     Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study.
     J Thorac Oncol. 2024 Dec 9:S1556-0864(24)02503.
     PubMed     Abstract available
     
     
     
103. PHILLIPS WJ, Watson AS, Camidge DR
     The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.
     J Thorac Oncol. 2024 Dec 4:S1556-0864(24)02498.
     PubMed     Abstract available
     
     
     
104. XU X, Xie J, Luo Z
     Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer.
     J Thorac Oncol. 2024;19:e94-e95.
     PubMed    
     
     
     
105. LI Z, Liu J, Liu H, Wu C, et al
     Comment on "A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology".
     J Thorac Oncol. 2024;19:e89-e90.
     PubMed    
     
     
     
106. ZHOU RX, Ye DW
     Reply to the Letter to the Editor: The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
     J Thorac Oncol. 2024;19:e82-e84.
     PubMed    
     
     
     
107. WANG L, Wang Z, Wang G
     The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
     J Thorac Oncol. 2024;19:e81-e82.
     PubMed    
     
     
     
108. JENSEN SO, Moore DA, Surani AA, Crosbie PAJ, et al
     Second Primary Lung Cancer-Potential Areas of Ambiguity.
     J Thorac Oncol. 2024;19:e101-e102.
     PubMed    
     
     
     
109. NIU Y, Xie J, Li Z
     Second Primary Lung Cancer-Potential Areas of Ambiguity.
     J Thorac Oncol. 2024;19:e100-e101.
     PubMed    
     
     
     
110. GUISSEVE A, Mualinque A, Cossa M, Jerez AD, et al
     Lung Cancer in Mozambique.
     J Thorac Oncol. 2024;19:1599-1605.
     PubMed    
     
     
     
111. TONG BC, Stinchcombe TE
     Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.
     J Thorac Oncol. 2024;19:1589-1590.
     PubMed    
     
     
     
112. KOZONO D, Hua X, Wu MC, Tolba KA, et al
     Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
     J Thorac Oncol. 2024;19:1618-1629.
     PubMed     Abstract available
     
     
     November 2024
113. HEERSCHE N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, et al
     Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer.
     J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488.
     PubMed     Abstract available
     
     
     
114. KAZI A, Kantilal Vasiyani HK, Ghosh D, Bandyopadhyay D, et al
     FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.
     J Thorac Oncol. 2024 Nov 25:S1556-0864(24)02485.
     PubMed     Abstract available
     
     
     
115. IGNATIUS OU SH, Solomon BJ, Besse B, Bearz A, et al
     Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study.
     J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02484.
     PubMed     Abstract available
     
     
     
116. DAMARAJU V, Krushna Karri JK, Gandrakota G, Marimuthu Y, et al
     Low dose computed tomography for lung cancer screening in Tuberculosis endemic countries: A Systematic Review and Meta-analysis.
     J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02483.
     PubMed     Abstract available
     
     
     
117. LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al
     PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.
     J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446.
     PubMed     Abstract available
     
     
     
118. ZHAO S, Zhou H, Yang N, Wang Z, et al
     Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
     J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445.
     PubMed     Abstract available
     
     
     
119. TUMINELLO S, Flores R, Untalan M, Ivic-Pavlicic T, et al
     Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.
     J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02444.
     PubMed     Abstract available
     
     
     
120. ECHEPARE M, Picabea B, Arricibita A, Teijeira A, et al
     DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.
     J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438.
     PubMed     Abstract available
     
     
     
121. GRAY JE, Schenker M, Nahit Sendur MA, Leonova V, et al
     The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
     J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435.
     PubMed     Abstract available
     
     
     
122. KARIM NA, Miao J, Reckamp KL, Gay CM, et al
     Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
     J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431.
     PubMed     Abstract available
     
     
     
123. OLTEANU GE, Vigdorovits A, Barna RA, Mazilu L, et al
     Lung Cancer in Romania.
     J Thorac Oncol. 2024;19:1492-1503.
     PubMed    
     
     
     
124. D'AMOURS MF, Hughesman CB, Yip ST, Ho C, et al
     The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.
     J Thorac Oncol. 2024;19:1479-1481.
     PubMed    
     
     
     
125. ADJEI AA
     How Can We Conquer Lung Cancer?
     J Thorac Oncol. 2024;19:1477-1478.
     PubMed    
     
     
     
126. KINDLER HL, Rosenthal A, Giroux DJ, Nowak AK, et al
     The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:1564-1577.
     PubMed     Abstract available
     
     
     
127. PARIKH K, Dimou A, Leventakos K, Mansfield AS, et al
     Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
     J Thorac Oncol. 2024;19:1539-1549.
     PubMed     Abstract available
     
     
     
128. HONG TH, Hwang S, Dasgupta A, Abbosh C, et al
     Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.
     J Thorac Oncol. 2024;19:1512-1524.
     PubMed     Abstract available
     
     
     October 2024
129. HOCHMAIR M, Schenker M, Dols MC, Kim TM, et al
     Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
     J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420.
     PubMed     Abstract available
     
     
     
130. CHEN Z, Wu L, Wang Q, Yu Y, et al
     Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial.
     J Thorac Oncol. 2024 Oct 26:S1556-0864(24)02421.
     PubMed     Abstract available
     
     
     
131. UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al
     Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.
     J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378.
     PubMed     Abstract available
     
     
     
132. PETERS S, Paz-Ares LG, Reck M, Carbone DP, et al
     Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
     J Thorac Oncol. 2024 Oct 4:S1556-0864(24)02355.
     PubMed     Abstract available
     
     
     
133. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
     A Response to the Letter to the Editor: "Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
     J Thorac Oncol. 2024;19:e57-e59.
     PubMed    
     
     
     
134. XU Z, Jiang J, Guo H, Zhao D, et al
     Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
     J Thorac Oncol. 2024;19:e56-e57.
     PubMed    
     
     
     
135. RAMI-PORTA R, Call S, Sanz-Santos J
     Reply to "Impact of the Ninth IASLC TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging" by Faria et al.
     J Thorac Oncol. 2024;19:e55-e56.
     PubMed    
     
     
     
136. FARIA N, Costa MI, Lacerda C, Sucena M, et al
     Impact of the Ninth International Association for the Study of Lung Cancer TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging.
     J Thorac Oncol. 2024;19:e53-e55.
     PubMed    
     
     
     
137. KOHNO T, Mochizuki A
     Response to Letter to the Editor.
     J Thorac Oncol. 2024;19:e52-e53.
     PubMed    
     
     
     
138. GU X, Han Z, Shi W
     Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".
     J Thorac Oncol. 2024;19:e51-e52.
     PubMed    
     
     
     
139. ZHUANG WT, Hu LY, Fang WF
     Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
     J Thorac Oncol. 2024;19:e50-e51.
     PubMed    
     
     
     
140. PAN Y
     Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
     J Thorac Oncol. 2024;19:e49-e50.
     PubMed    
     
     
     
141. SHI Y
     A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
     J Thorac Oncol. 2024;19:e48.
     PubMed    
     
     
     
142. GE MW, Chen HL
     Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
     J Thorac Oncol. 2024;19:e47-e48.
     PubMed    
     
     
     
143. CABALLE-PEREZ E, Cabrera-Miranda L, Arrieta O
     Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income Countries: Bridging the Gap in Global Cancer Care.
     J Thorac Oncol. 2024;19:1367-1369.
     PubMed    
     
     
     
144. PUJOL JL, Erich Eberhardt WE
     Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is Probably Underestimated but Specific Genotypic Features and Some Particular Disease Characteristics Should Help Their Screening.
     J Thorac Oncol. 2024;19:1364-1366.
     PubMed    
     
     
     
145. SOO RA, Reungwetwattana T, Perroud HA, Batra U, et al
     Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.
     J Thorac Oncol. 2024;19:1449-1459.
     PubMed     Abstract available
     
     
     
146. PAN K, Owens J, Elamin Y, Lu C, et al
     Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations.
     J Thorac Oncol. 2024;19:1438-1448.
     PubMed     Abstract available
     
     
     
147. BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al
     Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
     J Thorac Oncol. 2024;19:1460-1466.
     PubMed     Abstract available
     
     
     September 2024
148. SAID BI, Geng Y, Badiyan SN, Bang A, et al
     Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
     J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353.
     PubMed     Abstract available
     
     
     
149. PARK HS, Rimner A, Amini A, Chang JY, et al
     Executive Summary of the American Radium Society(R) (ARS) Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Systematic Review and Guidelines.
     J Thorac Oncol. 2024 Sep 11:S1556-0864(24)02268.
     PubMed     Abstract available
     
     
     
150. NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al
     Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265.
     PubMed     Abstract available
     
     
     
151. CHEN H, Yang S, Wang L, Wu Y, et al
     High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study.
     J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269.
     PubMed     Abstract available
     
     
     
152. HORNE A, Harada K, Brown KD, Lee Min Chua K, et al
     Erratum to "Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164-1185]".
     J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775.
     PubMed    
     
     
     
153. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
     A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e44-e45.
     PubMed    
     
     
     
154. JIANG Y, Zhang L
     Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e43.
     PubMed    
     
     
     
155. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
     A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
     J Thorac Oncol. 2024;19:e41-e43.
     PubMed    
     
     
     
156. ROMA L, Bubendorf L
     Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
     J Thorac Oncol. 2024;19:e38-e39.
     PubMed    
     
     
     
157. ZHOU L, Li M, Li W
     Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
     J Thorac Oncol. 2024;19:e37-e38.
     PubMed    
     
     
     
158. TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al
     Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?".
     J Thorac Oncol. 2024;19:e36.
     PubMed    
     
     
     
159. NIU Y, Xie J, Li Z
     The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
     J Thorac Oncol. 2024;19:e34-e35.
     PubMed    
     
     
     
160. HIGASHIYAMA RI, Yoshida T
     A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
     J Thorac Oncol. 2024;19:e33-e34.
     PubMed    
     
     
     
161. HAN Z, Liu L, Jiang Y
     Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
     J Thorac Oncol. 2024;19:e31-e32.
     PubMed    
     
     
     
162. ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al
     Lung Cancer in Finland.
     J Thorac Oncol. 2024;19:1265-1271.
     PubMed    
     
     
     
163. YANG CY, Lee MR, Yang PC
     Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection.
     J Thorac Oncol. 2024;19:1261-1264.
     PubMed    
     
     
     
164. ROSSI S, Costa R, di Federico A, Lo Bianco F, et al
     Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
     J Thorac Oncol. 2024;19:1352-1355.
     PubMed     Abstract available
     
     
     
165. LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al
     Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
     J Thorac Oncol. 2024;19:1297-1309.
     PubMed     Abstract available
     
     
     
166. ROMA L, Ercan C, Conticelli F, Akyurek N, et al
     Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
     J Thorac Oncol. 2024;19:1284-1296.
     PubMed     Abstract available
     
     
     
167. GILL RR, Nowak AK, Giroux DJ, Eisele M, et al
     The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:1310-1325.
     PubMed     Abstract available
     
     
     August 2024
168. ZHOU Q, Meng X, Sun L, Huang D, et al
     Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study.
     J Thorac Oncol. 2024 Aug 8:S1556-0864(24)00762.
     PubMed     Abstract available
     
     
     
169. HUBER RM, Cavic M, Balata H, Kitts AB, et al
     From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.
     J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747.
     PubMed     Abstract available
     
     
     
170. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
     Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e29-e30.
     PubMed    
     
     
     
171. KOSAKA N, Kataoka Y
     Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e28.
     PubMed    
     
     
     
172. CAMERON RB, Hines JB, Torri V, Garassino MC, et al
     A Response Letter by Cameron et al.
     J Thorac Oncol. 2024;19:e26-e28.
     PubMed    
     
     
     
173. HUANG J, Osarogiagbon RU
     Author's Reply.
     J Thorac Oncol. 2024;19:e24.
     PubMed    
     
     
     
174. PONVILAWAN B, Subramanian J, Bansal D
     The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC.
     J Thorac Oncol. 2024;19:e24-e26.
     PubMed    
     
     
     
175. TRISOLINI R
     The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2024;19:e23.
     PubMed    
     
     
     
176. KUBO N
     Response to Letter to the Editor.
     J Thorac Oncol. 2024;19:e22.
     PubMed    
     
     
     
177. SHI L, Bao Z
     Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
     J Thorac Oncol. 2024;19:e21-e22.
     PubMed    
     
     
     
178. SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al
     Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not.
     J Thorac Oncol. 2024;19:1155-1163.
     PubMed     Abstract available
     
     
     
179. MAKAREM M, Janne PA
     "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC.
     J Thorac Oncol. 2024;19:1151-1154.
     PubMed    
     
     
     
180. ZHENG MM, Wu YL
     "Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.
     J Thorac Oncol. 2024;19:1146-1150.
     PubMed    
     
     
     
181. LAISAAR T, Innos K, Jaal J, Oselin K, et al
     Lung Cancer in Estonia.
     J Thorac Oncol. 2024;19:1138-1145.
     PubMed    
     
     
     
182. WOODARD GA, Jablons DM
     Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
     J Thorac Oncol. 2024;19:1135-1137.
     PubMed    
     
     
     
183. TURK MA
     Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
     J Thorac Oncol. 2024;19:1133-1134.
     PubMed    
     
     
     
184. PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al
     Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC.
     J Thorac Oncol. 2024;19:1128-1132.
     PubMed    
     
     
     
185. GRAY SG, Mutti L, Meirson T
     Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
     J Thorac Oncol. 2024;19:1125-1127.
     PubMed    
     
     
     
186. HU LY, Zhuang WT, Chen MJ, Liao J, et al
     EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
     J Thorac Oncol. 2024;19:1186-1200.
     PubMed     Abstract available
     
     
     
187. WOLF AS, Eisele M, Giroux DJ, Gill R, et al
     The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:1242-1252.
     PubMed     Abstract available
     
     
     July 2024
188. VAN ROSSUM PSN, Wolfhagen N, van Bockel LW, Coremans IEM, et al
     Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
     J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684.
     PubMed     Abstract available
     
     
     
189. JENSEN SO, Moore DA, Surani AA, Crosbie PA, et al
     Second Primary Lung Cancer - an emerging issue in lung cancer survivors.
     J Thorac Oncol. 2024 Jul 24:S1556-0864(24)00683.
     PubMed     Abstract available
     
     
     
190. GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
     Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
     J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
     PubMed     Abstract available
     
     
     
191. JUN S, Shukla NA, Durm G, Hui AB, et al
     Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
     PubMed     Abstract available
     
     
     
192. LIN YL, Wang GS, Wei JC
     Rheumatoid Arthritis and Risk of Lung Cancer.
     J Thorac Oncol. 2024;19:e15-e16.
     PubMed    
     
     
     
193. YANG JJ, Wen W, Zheng W, Shu XO, et al
     "Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
     J Thorac Oncol. 2024;19:e14-e15.
     PubMed    
     
     
     
194. SHEN LT, Chen HL
     Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
     J Thorac Oncol. 2024;19:e13-e14.
     PubMed    
     
     
     
195. AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
     Lung Cancer in Ghana.
     J Thorac Oncol. 2024;19:966-972.
     PubMed    
     
     
     
196. MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
     Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
     J Thorac Oncol. 2024;19:984-994.
     PubMed     Abstract available
     
     
     June 2024
197. SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al
     Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
     J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627.
     PubMed     Abstract available
     
     
     
198. HSU CK, Lai CC
     Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
     J Thorac Oncol. 2024;19:e9.
     PubMed    
     
     
     
199. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
     Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
     J Thorac Oncol. 2024;19:e11-e12.
     PubMed    
     
     
     
200. CHO MH, Cho JH, Shin DW
     In Response.
     J Thorac Oncol. 2024;19:e10.
     PubMed    
     
     
     
201. RICCIUTI B, Garassino MC
     Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
     J Thorac Oncol. 2024;19:877-882.
     PubMed    
     
     
     
202. DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al
     The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
     J Thorac Oncol. 2024;19:862-865.
     PubMed    
     
     
     
203. UGALDE FIGUEROA P, Lacroix V, Van Schil PE
     Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
     J Thorac Oncol. 2024;19:858-861.
     PubMed    
     
     
     
204. LI MS, Ou SI
     Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come.
     J Thorac Oncol. 2024;19:855-857.
     PubMed    
     
     
     
205. PECCATORI FA, Florez N, Imbimbo M
     From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients With Lung Cancer.
     J Thorac Oncol. 2024;19:852-854.
     PubMed    
     
     
     May 2024
206. ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al
     A real-world assessment of stage I lung cancer through electronic nose technology.
     J Thorac Oncol. 2024 May 16:S1556-0864(24)00211.
     PubMed     Abstract available
     
     
     
207. BILLE A, Ripley RT, Giroux DJ, Gill RR, et al
     The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024 May 9:S1556-0864(24)00208.
     PubMed     Abstract available
     
     
     
208. NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al
     The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024 May 9:S1556-0864(24)00207.
     PubMed     Abstract available
     
     
     
209. NASSAR AH, Kim SY, Adib E, Naqash AR, et al
     Response letter by Nassar et al.
     J Thorac Oncol. 2024;19:e7-e8.
     PubMed    
     
     
     
210. CHEN CY, Wang GS, Wei JC
     Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
     J Thorac Oncol. 2024;19:e6-e7.
     PubMed    
     
     
     
211. ZHAO B, Yao L, Ma W
     Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
     J Thorac Oncol. 2024;19:e5-e6.
     PubMed    
     
     
     
212. SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
     Lung Cancer in Brunei Darussalam.
     J Thorac Oncol. 2024;19:698-705.
     PubMed    
     
     
     
213. LI Y, Adusumilli PS, Chou TY, Kadota K, et al
     Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
     J Thorac Oncol. 2024;19:677-697.
     PubMed     Abstract available
     
     
     
214. BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
     Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
     J Thorac Oncol. 2024;19:671-676.
     PubMed    
     
     
     
215. SHIH JY
     ERBB2 Amplification in NSCLC: How Many Faces?
     J Thorac Oncol. 2024;19:668-670.
     PubMed    
     
     
     
216. ISHIKAWA S
     Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
     J Thorac Oncol. 2024;19:666-667.
     PubMed    
     
     
     
217. WOODARD GA, Dacic S
     Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
     J Thorac Oncol. 2024;19:663-665.
     PubMed    
     
     
     
218. LUO J, Sanchez M, Lee E, Hertzler H, et al
     Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
     J Thorac Oncol. 2024;19:829-838.
     PubMed     Abstract available
     
     
     
219. OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
     Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
     J Thorac Oncol. 2024;19:706-718.
     PubMed     Abstract available
     
     
     April 2024
220. GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
     Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
     J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
     PubMed     Abstract available
     
     
     
221. ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
     Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
     J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
     PubMed     Abstract available
     
     
     
222. HORNE A, Harada K, Brown KD, Chua KLM, et al
     Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
     J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
     PubMed     Abstract available
     
     
     
223. KIM IH, Lee GD, Choi S, Kim HR, et al
     Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
     J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
     PubMed     Abstract available
     
     
     
224. SHUKLA V, Wang H, Varticovski L, Baek S, et al
     Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
     PubMed     Abstract available
     
     
     
225. DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
     The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
     J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
     PubMed     Abstract available
     
     
     
226. CHANG CL, Lin KC, Chen WM, Shia BC, et al
     Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
     J Thorac Oncol. 2024;19:e2-e4.
     PubMed    
     
     
     
227. CHIOU CC, Lai TY
     Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
     J Thorac Oncol. 2024;19:e1-e2.
     PubMed    
     
     
     
228. SMESSEIM I, Baas P
     Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
     J Thorac Oncol. 2024;19:547-550.
     PubMed    
     
     
     
229. GRAY SG, Meirson T, Mutti L
     Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
     J Thorac Oncol. 2024;19:541-546.
     PubMed    
     
     
     
230. SAIFO M, Alali M, Alhabeb H, Awak M, et al
     Lung Cancer in Syria.
     J Thorac Oncol. 2024;19:534-540.
     PubMed    
     
     
     
231. SHOENBILL KA, Goldstein AO
     Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
     J Thorac Oncol. 2024;19:531-533.
     PubMed    
     
     
     
232. ZHU Z, Chen H
     Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
     J Thorac Oncol. 2024;19:528-530.
     PubMed    
     
     
     
233. LEE JB, Nagasaka M
     Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
     J Thorac Oncol. 2024;19:525-527.
     PubMed    
     
     
     
234. LEONG TL, McWilliams A, Wright GM
     Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
     J Thorac Oncol. 2024;19:522-524.
     PubMed    
     
     
     
235. DWYER LJ, Singhal N, Yu B, Kao S, et al
     Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
     J Thorac Oncol. 2024;19:650-652.
     PubMed     Abstract available
     
     
     
236. RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
     Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
     J Thorac Oncol. 2024;19:626-635.
     PubMed     Abstract available
     
     
     
237. MCNAMEE N, Harvey C, Gray L, Khoo T, et al
     Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
     J Thorac Oncol. 2024;19:636-642.
     PubMed     Abstract available
     
     
     
238. NEL AE, Pavlisko EN, Roggli VL
     The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
     J Thorac Oncol. 2024;19:551-564.
     PubMed     Abstract available
     
     
     March 2024
239. TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
     The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
     J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
     PubMed     Abstract available
     
     
     
240. BORGEAUD M, Parikh K, Banna GL, Kim F, et al
     Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
     J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
     PubMed     Abstract available
     
     
     
241. HINES JB, Cameron RB, Esposito A, Kim L, et al
     Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
     J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
     PubMed     Abstract available
     
     
     
242. CHENG Y, Fan Y, Zhao Y, Huang D, et al
     Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
     J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
     PubMed     Abstract available
     
     
     
243. RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
     The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
     PubMed     Abstract available
     
     
     
244. KIM BG, Yoon S, Lee SY, Sohn JW, et al
     How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
     J Thorac Oncol. 2024;19:509-510.
     PubMed    
     
     
     
245. WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
     Lung Cancer in Switzerland.
     J Thorac Oncol. 2024;19:385-394.
     PubMed    
     
     
     
246. TEN HAAF K
     Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
     J Thorac Oncol. 2024;19:373-375.
     PubMed    
     
     
     
247. LI CP, Tsai RY, Chang HC, Gau SY, et al
     Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
     J Thorac Oncol. 2024;19:507-508.
     PubMed    
     
     
     
248. CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
     Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
     J Thorac Oncol. 2024;19:380-384.
     PubMed    
     
     
     
249. LIM SM, Lee JB, Cho BC
     Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
     J Thorac Oncol. 2024;19:376-379.
     PubMed    
     
     
     
250. YALAMANCHALI A, Hassan KA
     MUC1-C: The Occam Razor of Osimertinib Resistance?
     J Thorac Oncol. 2024;19:370-372.
     PubMed    
     
     
     
251. DAMMEIJER F, Dumoulin DW, Aerts JGJV
     Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
     J Thorac Oncol. 2024;19:366-369.
     PubMed    
     
     
     
252. CANI M, Novello S, Bironzo P
     Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
     J Thorac Oncol. 2024;19:363-365.
     PubMed    
     
     
     
253. BORCZUK AC
     Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
     J Thorac Oncol. 2024;19:360-362.
     PubMed    
     
     
     
254. YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
     Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
     J Thorac Oncol. 2024;19:409-424.
     PubMed     Abstract available
     
     
     February 2024
255. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
     The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
     J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
     PubMed     Abstract available
     
     
     
256. ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
     Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
     J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
     PubMed     Abstract available
     
     
     
257. TORASAWA M, Horinouchi H
     A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
     J Thorac Oncol. 2024;19:351-352.
     PubMed    
     
     
     
258. NISHIMURA T
     A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
     J Thorac Oncol. 2024;19:350.
     PubMed    
     
     
     
259. HORITA N, Takase-Minegishi K
     Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
     J Thorac Oncol. 2024;19:348.
     PubMed    
     
     
     
260. CHANG HC, Gau SY
     Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
     J Thorac Oncol. 2024;19:346.
     PubMed    
     
     
     
261. YUAN C, Huang R, Wang Y
     An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
     J Thorac Oncol. 2024;19:344-345.
     PubMed    
     
     
     
262. BERMAS BL, Gerber DE
     The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
     J Thorac Oncol. 2024;19:196-198.
     PubMed    
     
     
     
263. VOKES EE, Mornex F, Sezer A, Cheng Y, et al
     Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
     J Thorac Oncol. 2024;19:285-296.
     PubMed     Abstract available
     
     
     
264. REMON J, Saw SPL, Cortiula F, Singh PK, et al
     Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
     J Thorac Oncol. 2024;19:199-215.
     PubMed     Abstract available
     
     
     
265. DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
     Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
     J Thorac Oncol. 2024;19:273-284.
     PubMed     Abstract available
     
     
     
266. OWONIKOKO TK
     SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
     J Thorac Oncol. 2024;19:193-195.
     PubMed    
     
     
     
267. LE X
     Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
     J Thorac Oncol. 2024;19:190-192.
     PubMed    
     
     
     
268. LEE JH
     Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
     J Thorac Oncol. 2024;19:187-189.
     PubMed    
     
     
     
269. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
     Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
     J Thorac Oncol. 2024;19:337-343.
     PubMed     Abstract available
     
     
     January 2024
270. SHI Y, Hu X, Li X, Gong C, et al
     Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
     J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
     PubMed     Abstract available
     
     
     
271. SHI Y, Chen J, Yang R, Wu H, et al
     Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
     J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
     PubMed     Abstract available
     
     
     
272. NASSAR AH, Kim SY, Aredo JV, Feng J, et al
     Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
     J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
     PubMed     Abstract available
     
     
     
273. SIMONS E, Camidge DR
     Lung cancer oncogene-directed therapy, fertility and pregnancy.
     J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
     PubMed     Abstract available
     
     
     
274. YU S, Feng J
     Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
     J Thorac Oncol. 2024;19:173-174.
     PubMed    
     
     
     
275. TANIZAKI J, Hayashi H
     Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
     J Thorac Oncol. 2024;19:15-17.
     PubMed    
     
     
     
276. BATAH H, Majeed Z, Moudgil R
     Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
     J Thorac Oncol. 2024;19:13-14.
     PubMed    
     
     
     
277. SINGHAL S, Gandara D, Riess JW
     Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
     J Thorac Oncol. 2024;19:10-12.
     PubMed    
     
     
     
278. FANG W, Girard N, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2024;19:52-70.
     PubMed     Abstract available
     
     
     
279. CHEN MF, Harada G, Liu D, DeMatteo R, et al
     Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
     J Thorac Oncol. 2024;19:153-159.
     PubMed     Abstract available
     
     
     
280. UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
     HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
     J Thorac Oncol. 2024;19:106-118.
     PubMed     Abstract available
     
     
     
281. HAMADA A, Suda K, Nishino M, Obata K, et al
     Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
     J Thorac Oncol. 2024;19:71-79.
     PubMed     Abstract available
     
     
     
282. LAM S, Wynes MW, Connolly C, Ashizawa K, et al
     The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
     J Thorac Oncol. 2024;19:94-105.
     PubMed     Abstract available
     
     
     
283. TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
     Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:166-172.
     PubMed     Abstract available
     
     
     December 2023
284. YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
     Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
     J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
     PubMed     Abstract available
     
     
     
285. ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
     Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
     PubMed     Abstract available
     
     
     
286. BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
     Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
     J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
     PubMed     Abstract available
     
     
     
287. VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
     The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
     PubMed     Abstract available
     
     
     
288. LI W, Fei K, Guo L, Wang Y, et al
     CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
     J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
     PubMed     Abstract available
     
     
     
289. DACIC S, Travis WD, Giltnane JM, Kos F, et al
     Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
     J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
     PubMed     Abstract available
     
     
     
290. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
     Lung Cancer in Albania.
     J Thorac Oncol. 2023;18:1632-1637.
     PubMed    
     
     
     
291. FERREIRA M, Redman MW, Reckamp KL
     Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
     J Thorac Oncol. 2023;18:1629-1631.
     PubMed    
     
     
     
292. LI Z, Lu S
     Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
     J Thorac Oncol. 2023;18:1625-1628.
     PubMed    
     
     
     
293. MAKAREM M, Rotow JK
     Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
     J Thorac Oncol. 2023;18:1615-1617.
     PubMed    
     
     
     
294. RUFFINI E, Huang J, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2023;18:1655-1671.
     PubMed     Abstract available
     
     
     
295. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
     J Thorac Oncol. 2023;18:1672-1688.
     PubMed     Abstract available
     
     
     
296. OKUMURA M, Marino M, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2023;18:1638-1654.
     PubMed     Abstract available
     
     
     
297. ANG YLE, Soo RA
     Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
     J Thorac Oncol. 2023;18:1621-1624.
     PubMed    
     
     
     
298. MEDINA CG, Xu Y, Ripley RT
     International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
     J Thorac Oncol. 2023;18:1618-1620.
     PubMed    
     
     
     
299. SOO RA, Cho BC, Kim JH, Ahn MJ, et al
     Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
     J Thorac Oncol. 2023;18:1756-1766.
     PubMed     Abstract available
     
     
     
300. WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
     The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
     J Thorac Oncol. 2023;18:1689-1702.
     PubMed     Abstract available
     
     
     November 2023
301. WANG K, Du R, Myall NJ, Lewis WE, et al
     BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
     J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
     PubMed     Abstract available
     
     
     
302. O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
     Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
     J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
     PubMed     Abstract available
     
     
     
303. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
     Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
     J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
     PubMed     Abstract available
     
     
     
304. LU C, Wei XW, Wang Z, Zhou Z, et al
     Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
     J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
     PubMed     Abstract available
     
     
     
305. HENSCHKE C, Huber R, Jiang L, Yang D, et al
     Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
     J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
     PubMed     Abstract available
     
     
     
306. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
     Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
     J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
     PubMed     Abstract available
     
     
     
307. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
     No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
     J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
     PubMed     Abstract available
     
     
     
308. YANG JJ, Wen W, Zahed H, Zheng W, et al
     Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
     J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
     PubMed     Abstract available
     
     
     
309. KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
     Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
     J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
     PubMed     Abstract available
     
     
     
310. HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
     MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
     J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
     PubMed     Abstract available
     
     
     
311. HONG TH, Hwang S, Cho J, Choi YL, et al
     Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
     J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
     PubMed     Abstract available
     
     
     
312. QIU Z, Huang H, Zhang Y, Chen D, et al
     Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
     J Thorac Oncol. 2023;18:e138-e139.
     PubMed    
     
     
     
313. LI A, Yang Y, Zhang L, Hong S, et al
     STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
     J Thorac Oncol. 2023;18:e135-e138.
     PubMed    
     
     
     
314. AMORI G, Sugawara E, Inamura K
     Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
     J Thorac Oncol. 2023;18:e134-e135.
     PubMed    
     
     
     
315. CHEN WM, Yu YH, Chen M, Shia BC, et al
     Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
     J Thorac Oncol. 2023;18:e132-e134.
     PubMed    
     
     
     
316. ZHANG Y, Dai K, He D, Chen Z, et al
     The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
     J Thorac Oncol. 2023;18:e130-e131.
     PubMed    
     
     
     
317. NIU Y, Yao F, Yang H
     "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
     J Thorac Oncol. 2023;18:e126-e128.
     PubMed    
     
     
     
318. MARTI JLG, Wells JZ, Wells A
     Statins as a Secondary Preventive Agent for Metastatic Cancer.
     J Thorac Oncol. 2023;18:e125-e126.
     PubMed    
     
     
     
319. OKONTA KE, Baiyewu LA, Jimoh MA
     Lung Cancer in Nigeria.
     J Thorac Oncol. 2023;18:1446-1457.
     PubMed    
     
     
     
320. DAGOGO-JACK I
     We Don't Talk (Enough) About BRAF.
     J Thorac Oncol. 2023;18:1443-1445.
     PubMed    
     
     
     
321. LEE JB, Ou SI
     Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
     J Thorac Oncol. 2023;18:1434-1442.
     PubMed    
     
     
     
322. HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
     A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
     J Thorac Oncol. 2023;18:1431-1433.
     PubMed    
     
     
     
323. SOZZI G, Pastorino U
     Small RNAs Do It Better.
     J Thorac Oncol. 2023;18:1428-1430.
     PubMed    
     
     
     
324. YANKELEVITZ DF, Yip R, Henschke CI
     Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
     J Thorac Oncol. 2023;18:1426-1427.
     PubMed    
     
     
     
325. SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
     Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
     J Thorac Oncol. 2023;18:1538-1549.
     PubMed     Abstract available
     
     
     
326. AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
     Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
     J Thorac Oncol. 2023;18:1594-1606.
     PubMed     Abstract available
     
     
     October 2023
327. WANG L, Luo Y, Ren S, Zhang Z, et al
     A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
     J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
     PubMed     Abstract available
     
     
     
328. HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
     The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
     PubMed     Abstract available
     
     
     
329. CHO MH, Cho JH, Eun Y, Han K, et al
     Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
     J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
     PubMed     Abstract available
     
     
     
330. STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
     Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
     J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
     PubMed     Abstract available
     
     
     
331. HENSCHKE CI, Yip R, Sun Q, Li P, et al
     Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
     J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
     PubMed     Abstract available
     
     
     
332. ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
     Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
     J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
     PubMed     Abstract available
     
     
     
333. TRIPHURIDET N, Gao Y, Ou SI
     Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
     J Thorac Oncol. 2023;18:e122-e123.
     PubMed    
     
     
     
334. JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
     Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
     J Thorac Oncol. 2023;18:e118-e122.
     PubMed    
     
     
     
335. CHOUR A, Duruisseaux M
     Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
     J Thorac Oncol. 2023;18:e114-e115.
     PubMed    
     
     
     
336. DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
     The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
     J Thorac Oncol. 2023;18:1258-1260.
     PubMed    
     
     
     
337. INAMURA K
     Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
     J Thorac Oncol. 2023;18:e109-e110.
     PubMed    
     
     
     
338. ADJEI AA
     The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
     J Thorac Oncol. 2023;18:1257.
     PubMed    
     
     
     
339. HOE HJ, Balasubramanian A, John T
     LASERing FLAURAL Arrangements in Asian EGFR Subsets.
     J Thorac Oncol. 2023;18:1261-1264.
     PubMed    
     
     
     
340. REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
     Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
     J Thorac Oncol. 2023;18:1351-1361.
     PubMed     Abstract available
     
     
     
341. PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
     Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
     J Thorac Oncol. 2023;18:1362-1385.
     PubMed     Abstract available
     
     
     
342. GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
     Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
     J Thorac Oncol. 2023;18:e112-e113.
     PubMed    
     
     
     
343. CHEN WM, Yu YH, Chen M, Shia BC, et al
     Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
     J Thorac Oncol. 2023;18:e107-e109.
     PubMed    
     
     
     
344. LIN TA, Chen SY, Chang R, Sun CK, et al
     Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
     J Thorac Oncol. 2023;18:e105-e106.
     PubMed    
     
     
     
345. WRIGHT K, Digby GC, Gyawali B, Jad R, et al
     Malignant Superior Vena Cava Syndrome: A Scoping Review.
     J Thorac Oncol. 2023;18:1268-1276.
     PubMed     Abstract available
     
     
     September 2023
346. DUAN J, Wu L, Yang K, Zhao J, et al
     Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
     J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
     PubMed     Abstract available
     
     
     
347. RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
     Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
     J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
     PubMed     Abstract available
     
     
     
348. JIANG C, Zhang Y, Fu F, Deng P, et al
     A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
     J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
     PubMed     Abstract available
     
     
     
349. TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
     Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
     J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
     PubMed     Abstract available
     
     
     
350. WANG X, Bai H, Zhang J, Wang Z, et al
     Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
     J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
     PubMed     Abstract available
     
     
     
351. FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
     Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
     J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
     PubMed     Abstract available
     
     
     
352. ZHANG S, Liu L, Shi S, He H, et al
     Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
     J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
     PubMed     Abstract available
     
     
     August 2023
353. DACIC S, Travis W, Redman M, Saqi A, et al
     International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
     J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
     PubMed     Abstract available
     
     
     
354. LIN SH
     Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
     J Thorac Oncol. 2023;18:970-971.
     PubMed    
     
     
     July 2023
355. RIMNER A, Ruffini E, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
     PubMed     Abstract available
     
     
     June 2023
356. PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
     Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
     J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.